JP7433463B2 - ピリミジン含有含窒素二環化合物 - Google Patents

ピリミジン含有含窒素二環化合物 Download PDF

Info

Publication number
JP7433463B2
JP7433463B2 JP2022553287A JP2022553287A JP7433463B2 JP 7433463 B2 JP7433463 B2 JP 7433463B2 JP 2022553287 A JP2022553287 A JP 2022553287A JP 2022553287 A JP2022553287 A JP 2022553287A JP 7433463 B2 JP7433463 B2 JP 7433463B2
Authority
JP
Japan
Prior art keywords
group
alkyl
salt
mmol
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022553287A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022070289A1 (https=
Inventor
浩一郎 新井
健一郎 鷹羽
公和 跡部
好聖 高島
直美 青野
アンドリュー ジョン ポッター
ダニエル ポール マドックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of JPWO2022070289A1 publication Critical patent/JPWO2022070289A1/ja
Application granted granted Critical
Publication of JP7433463B2 publication Critical patent/JP7433463B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022553287A 2020-09-30 2020-09-30 ピリミジン含有含窒素二環化合物 Active JP7433463B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/037048 WO2022070289A1 (ja) 2020-09-30 2020-09-30 ピリミジン含有含窒素二環化合物

Publications (2)

Publication Number Publication Date
JPWO2022070289A1 JPWO2022070289A1 (https=) 2022-04-07
JP7433463B2 true JP7433463B2 (ja) 2024-02-19

Family

ID=80951519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553287A Active JP7433463B2 (ja) 2020-09-30 2020-09-30 ピリミジン含有含窒素二環化合物

Country Status (11)

Country Link
US (1) US12590090B2 (https=)
EP (1) EP4223750B1 (https=)
JP (1) JP7433463B2 (https=)
KR (1) KR20230084145A (https=)
CN (1) CN116194454B (https=)
AU (1) AU2020471055B8 (https=)
CA (1) CA3194164A1 (https=)
ES (1) ES3036969T3 (https=)
MX (1) MX2023003698A (https=)
PL (1) PL4223750T3 (https=)
WO (1) WO2022070289A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068546A1 (en) 2010-11-19 2012-05-24 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2019070093A1 (en) 2017-10-02 2019-04-11 1ST Biotherapeutics, Inc. BENZOTHIAZOL COMPOUNDS AND METHODS OF USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003219A (zh) 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
US9169260B2 (en) * 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
EP2691399B1 (en) 2011-03-28 2016-07-13 F.Hoffmann-La Roche Ag Thiazolopyrimidine compounds
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
EP2802590B1 (en) 2012-01-10 2017-03-01 F. Hoffmann-La Roche AG Thienopyrimidine compounds
RU2548363C2 (ru) 2012-01-25 2015-04-20 Общество с ограниченной ответственностью "Асинэкс Медхим." СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Haspin киназы
CN106232122A (zh) 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
US9969749B2 (en) 2014-09-30 2018-05-15 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
CN108473498B (zh) * 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
CN106946890A (zh) * 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068546A1 (en) 2010-11-19 2012-05-24 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2019070093A1 (en) 2017-10-02 2019-04-11 1ST Biotherapeutics, Inc. BENZOTHIAZOL COMPOUNDS AND METHODS OF USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEIFETZ,A. et al.，Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Ce，Journal of Medicinal Chemistry，2016年，Vol.59, No.9，pp.4352-4363，DOI 10.1021/acs.jmedchem.6b00045
NAIR,S. et al.，Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Mod，ACS Medicinal Chemistry Letters，2020年06月10日，Vol.11, No.7，pp.1402-1409，DOI 10.1021/acsmedchemlett.0c00082

Also Published As

Publication number Publication date
WO2022070289A1 (ja) 2022-04-07
ES3036969T3 (en) 2025-09-25
US12590090B2 (en) 2026-03-31
AU2020471055B8 (en) 2023-12-21
CN116194454B (zh) 2025-02-18
PL4223750T3 (pl) 2025-09-15
EP4223750A4 (en) 2024-06-19
CA3194164A1 (en) 2022-04-07
JPWO2022070289A1 (https=) 2022-04-07
AU2020471055B2 (en) 2023-12-14
KR20230084145A (ko) 2023-06-12
MX2023003698A (es) 2023-06-15
CN116194454A (zh) 2023-05-30
US20240025893A1 (en) 2024-01-25
EP4223750A1 (en) 2023-08-09
EP4223750B1 (en) 2025-06-25
AU2020471055A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP6437140B2 (ja) ピロロピリミジン化合物による抗腫瘍効果増強剤
JP6192741B2 (ja) 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤
HUE026041T2 (en) Pyrrolo-triazinone derivatives as P13K inhibitors
BR112019015273A2 (pt) compostos
BR112019018688A2 (pt) derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
JP7433463B2 (ja) ピリミジン含有含窒素二環化合物
WO2018092916A1 (ja) 含窒素多環式ヘテロ環誘導体
TWI898106B (zh) 含有嘧啶之含氮雙環化合物
RU2827867C1 (ru) Пиримидин- и азотсодержащее бициклическое соединение
JP7422242B2 (ja) マクロサイクル化合物
CA3194090C (en) Polycyclic macrocyclic compounds and their use in irak-4 inhibition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240206

R150 Certificate of patent or registration of utility model

Ref document number: 7433463

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150